ArticleClinical journal of gastroenterology2026
Unusual metastatic recurrence of pulmonary adenocarcinoma with a focal neuroendocrine component presenting with bilateral renal metastases and an accompanying pancreatic neuroendocrine tumor-like lesion: a case report.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 72-year-old woman with a history of resected lung adenocarcinoma presented with a pancreatic mass and multiple bilateral renal masses. Endoscopic ultrasound-guided tissue acquisition of the pancreatic lesion showed neuroendocrine morphology, synaptophysin positivity, focal chromogranin A positivity, and a Ki-67 labeling index of 2%, leading to an initial diagnosis of pancreatic neuroendocrine tumor grade 1. Renal biopsy also demonstrated neuroendocrine differentiation with a Ki-67 labeling index of 17%. However, the pancreatic lesion was hypovascular and poorly defined, and the multifocal bilateral renal involvement was atypical for a low-grade pancreatic neuroendocrine tumor. Re-evaluation of the resected lung specimen revealed a focal neuroendocrine component showing large cell neuroendocrine carcinoma-like features, although the strict diagnostic criteria for such a diagnosis were not fully met. Genomic analysis identified a KRAS G12V mutation shared by the renal and lung tumors, supporting the interpretation that the renal lesions represented metastatic recurrence of the previously resected lung tumor. Direct molecular confirmation was unavailable for the pancreatic lesion because of insufficient residual endoscopic ultrasound-guided tissue acquisition material; therefore, its origin remained diagnostically uncertain. Nevertheless, based on the overall clinicopathological context, the pancreatic lesion was interpreted as an accompanying neuroendocrine tumor-like lesion most consistent with metastatic recurrence. This case highlights the importance of integrating clinical history, imaging features, disease distribution, archival pathology, and molecular findings when evaluating neuroendocrine tumor-like lesions in patients with a prior malignancy.
Indexed as
Identifiers
42909554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.